Research Article
Variability in Estimated Glomerular Filtration Rate by Area under the Curve Predicts Renal Outcomes in Chronic Kidney Disease
Table 2
Comparison of baseline characteristics between patients with and without renal end point.
| | Characteristics | Number of patients with data available | All patients () | Without renal end point () | With renal end point () |
| | Age (year) | 1862 | 63.6 ± 13.4 | 64.4 ± 13.2 | 61.6 ± 13.7** | | Male gender (%) | 1862 | 58.2 | 62.9 | 47.3** | | Diabetes mellitus (%) | 1862 | 40.2 | 38.0 | 45.4* | | Hypertension (%) | 1862 | 65.1 | 62.3 | 71.6** | | Cardiovascular disease (%) | 1862 | 23.3 | 22.3 | 25.5 | | Systolic blood pressure (mmHg) | 1862 | 138.0 ± 20.3 | 136.2 ± 19.9 | 142.1 ± 20.7** | | Diastolic blood pressure (mmHg) | 1862 | 79.2 ± 12.4 | 79.0 ± 12.3 | 79.7 ± 12.8 | | Body mass index (kg/m2) | 1861 | 24.9 ± 4.0 | 25.0 ± 3.9 | 24.6 ± 4.0* | | CKD stage | 1862 | | | | | Stage 3 (%) | | 41.4 | 56.3 | 6.9** | | Stage 4 (%) | | 32.5 | 32.0 | 33.7 | | Stage 5 (%) | | 26.1 | 11.6 | 59.4 | | Laboratory parameters | | | | | | Albumin (g/dL) | 1837 | 3.9 ± 0.5 | 4.0 ± 0.5 | 3.7 ± 0.5** | | Fasting glucose (mg/dL) | 1842 | 116.4 ± 43.8 | 115.7 ± 42.7 | 118.2 ± 46.1 | | Triglyceride (mg/dL) | 1847 | 124.5 (91–185) | 123.5 (91–182.5) | 127 (90.9–193) | | Total cholesterol (mg/dL) | 1846 | 196.5 ± 51.7 | 196.4 ± 51.7 | 196.6 ± 51.9 | | Hemoglobin (g/dL) | 1858 | 11.3 ± 2.3 | 12.0 ± 2.2 | 9.8 ± 1.7** | | Baseline eGFR (mL/min/1.73 m2) | 1862 | 27.2 ± 14.2 | 32.2 ± 13.1 | 15.6 ± 9.0** | | Total calcium (mg/dL) | 1835 | 9.2 ± 0.7 | 9.3 ± 0.6 | 8.9 ± 0.9** | | Phosphorous (mg/dL) | 1839 | 4.2 ± 1.0 | 3.9 ± 0.8 | 4.9 ± 1.1** | | CaXP product (mg2/dL2) | 1832 | 38.4 ± 8.9 | 36.3 ± 7.4 | 43.4 ± 9.8** | | Uric acid (mg/dL) | 1846 | 7.8 ± 2.0 | 7.7 ± 1.9 | 8.0 ± 2.0** | | Urine protein-to-creatinine ratio (mg/g) | 1823 | 911.7 (362.3–1903.4) | 613.2 (255.7–1290.6) | 1871.2 (1047.1–3733.9)** | | ACEI and/or ARB use (%) | 1757 | 45.9 | 44.5 | 49.2 | | Days of follow-up (days) | 1862 | 873.5 (572–1282) | 954.5 (600–1372.5) | 724 (520–1086.8)** | | Variability of eGFR methods | | | | | | Initial eGFR AUC%_12M | 1862 | 96.8 ± 20.5 | 100.3 ± 21.3 | 88.5 ± 15.9** | | Peak eGFR AUC%_12M | 1862 | 85.8 ± 9.9 | 88.2 ± 8.6 | 80.4 ± 10.5** | | eGFR slope_12M | 1862 | −0.17 ± 0.03 | −0.07 ± 0.05 | −0.40 ± 0.03** |
|
|
CKD: chronic kidney disease; eGFR: estimated glomerular filtration rate; CaXP product: calcium-phosphorous product; ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin II receptor blocker.
, compared with patients without renal end point.
|
